Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2025-12-26 @ 5:25 AM
Study NCT ID:
NCT01785160
Status:
COMPLETED
Last Update Posted:
2015-08-03
First Post:
2012-12-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir
Sponsor:
Boehringer Ingelheim
Organization:
Study Overview
Official Title:
Investigation of Faldaprevir Effect on Steady State Pharmacokinetics of Raltegravir in Healthy Male and Female Volunteers (an Open-label Trial With Two Periods in a Fixed Sequence)
Status:
COMPLETED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this trial is to investigate effect of faldaprevir on steady state pharmacokinetics of raltegravir.
The assessment of safety and tolerability will be an additional objective of this trial.
The assessment of safety and tolerability will be an additional objective of this trial.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2012-004872-21 | EUDRACT_NUMBER | EudraCT | View |